topdol, tramadol capsules
 

Pills
 

ED Pills

ED Drugs
 

Imadol


Imadol may be available in the countries listed below.

Ingredient matches for Imadol Tramadol

Tramadol hydrochloride (a derivative of Tramadol) is reported as an ingredient of Imadol in the following countries:

Bangladesh

International Drug Name Search


read more / Download


Group IV antiarrhythmics


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

See also

Medical conditions associated with group IV antiarrhythmics:

Angina Angina Pectoris Prophylaxis Arrhythmia Atrial Fibrillation Atrial Flutter Bipolar Disorder Cluster Headaches Heart Failure High Blood Pressure Idiopathic Hypertrophic Subaortic Stenosis Migraine Prevention Nocturnal Leg Cramps Raynaud's Syndrome Supraventricular Tachycardia Drug List: Diltia-Xt-24-Hour-Sustained-Release-Capsules Diltiazem-Hydrochloride-Sr Cartia-Xt-24-Hour-Sustained-Release-Beads-Capsules Calan-Sr-Controlled-Release-Tablets Cardizem Isoptin-Sr-Controlled-Release-Tablets Tiazac Verelan-Pm-Sustained-Release-Capsules-Controlled-Onset Diltiazem-Hydrochloride-Cd Calan Cardizem-La-24-Hour-Extended-Release-Beads-Tablets Isoptin Cardizem-Cd-24-Hour-Sustained-Release-Beads-Capsules Verelan-Sustained-Release-Pellet-Filled-Capsules Taztia-Xt-24-Hour-Extended-Release-Beads-Capsules Covera-Hs-Sustained-Release-Tablets-Controlled-Onset Dilacor-Xr-24-Hour-Sustained-Release-Capsules Dilt-Xr-24-Hour-Sustained-Release-Capsules Diltiazem-Hydrochloride-Xr Diltiazem-Hydrochloride-Xt Diltzac Matzim-La
read more / Download


Atrial Fibrillation Medications


Definition of Atrial Fibrillation:

A condition where there is disorganised electrical conduction in the atria, resulting in ineffective pumping of blood into the ventricle.

Acronym: AF

Drugs associated with Atrial Fibrillation

The following drugs and medications are in some way related to, or used in the treatment of Atrial Fibrillation. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Atrial FibrillationPrevention of Thromboembolism in Atrial Fibrillation (24 drugs) Learn more about Atrial Fibrillation

Medical Encyclopedia:

Atrial fibrillation/flutter

Harvard Health Guide:

Symptoms and treatment for Atrial Fibrillation
Drug List:/tags/betapace-af/
/tags/cardizem/
/tags/cardizem-la-24-hour-extended-release-beads-tablets/
/tags/catapres/
/tags/coreg-cr-extended-release-capsules/
/tags/digitek/
/tags/dilt-xr-24-hour-sustained-release-capsules/
/tags/diltiazem-hydrochloride-cd/
/tags/diltiazem-hydrochloride-xr/
/tags/diltzac/
/tags/lanoxin/
/tags/matzim-la/
/tags/multaq/
/tags/rythmol-sr-sustained-release-capsules/
/tags/tambocor/
/tags/toprol/

read more / Download


Zamadol SR Capsules 50mg, 100mg, 150mg, 200mg


1. Name Of The Medicinal Product

Zamadol SR 50 mg prolonged-release hard capsules

Zamadol SR 100 mg prolonged-release hard capsules

Zamadol SR 150 mg prolonged-release hard capsules

Zamadol SR 200 mg prolonged-release hard capsules

2. Qualitative And Quantitative Composition

One capsule contains 50 mg, 100mg, 150mg, 200mg of tramadol hydrochloride

This product contains the excipients sucrose (9.375 18.75 28.125 37.5mg/capsule).

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Prolonged release hard capsule.

The 50 mg capsules are dark green and marked T50SR.

The 100 mg capsules are white and marked T100SR

The 150 mg capsules are dark green and marked T150SR

The 200 mg capsules are yellow and marked T200SR

4. Clinical Particulars 4.1 Therapeutic Indications

Treatment of moderate to severe pain.

4.2 Posology And Method Of Administration

The capsules are intended for twice daily oral administration and can be taken independently of meal times, swallowed whole with water.

As with all analgesic drugs the dosing of Zamadol SR prolonged-release hard capsules should be adjusted depending on the severity of the pain and the individual clinical response of the patient. The dose used should be the lowest dose that provides pain relief.

Adults:

The usual initial dose is 50-100 mg twice daily, morning and evening. This dose may be titrated up to 150-200 mg twice daily according to pain severity.

If long-term pain treatment with tramadol is necessary in view of the nature and severity of the illness, then careful and regular monitoring should be carried out (if necessary with breaks in treatment) to establish whether and to what extent further treatment is necessary.

A total oral daily dose of 400 mg should not be exceeded except in special clinical circumstances.

Elderly patients:

Dosing as for adults, however it should be noted that in patients over 75 years there tends to be an increase in absolute bioavailability of tramadol and a 17% increase in the terminal elimination half-life. An adjustment of the dosage or the dose interval may be required.

Patients with renal or hepatic insufficiency:

As the elimination of tramadol may be prolonged in patients with severe renal and/or hepatic impairment, the use of Zamadol SR prolonged-release hard capsulesis not recommended. In moderate cases an adjustment of the dosage interval may be required.

Patients who have difficulty in swallowing:

Zamadol SR prolonged-release hard capsules can be opened, carefully, so that the pellets are deposited on a spoon. The spoon and pellets should be taken into the mouth, followed by a drink of water to rinse the mouth of all pellets. The pellets must not be chewed or crushed.

Children and adolescents :

Over 12 years: Dosage as for adults.

Under 12 years: Zamadol SR prolonged-release hard capsules have not been studied in children. Therefore, safety and efficacy have not been established and the product should not be used in children.

4.3 Contraindications

Zamadol SR prolonged-release hard capsules should not be given to patients who have previously shown hypersensitivity to the active substance tramadol or to any of the other excipients.

The product should not be administered to patients suffering from acute intoxication with hypnotics, centrally acting analgesics, opioids, psychotropic drugs or alcohol.

Tramadol should not be administered to patients who are receiving monoamine oxidase inhibitors or within 2 weeks of their withdrawal.

Contra-indicated in patients suffering from uncontrolled epilepsy.

Tramadol must not be used for narcotic withdrawal treatment.

4.4 Special Warnings And Precautions For Use

Warnings:

Tramadol has a low dependence potential. On long-term use tolerance, psychic and physical dependence may develop. In patients with a tendency to drug abuse or dependence, treatment should be for short periods under strict medical supervision. In rare cases at therapeutic doses, tramadol has the potential to cause withdrawal symptoms.

Zamadol SR prolonged-release hard capsules are not a suitable substitute in opioid dependent patients. The product does not suppress morphine withdrawal symptoms although it is an opioid agonist.

Convulsions have been reported at therapeutic doses and the risk may be increased at doses exceeding the usual upper daily dose limit. Patients with a history of epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling reasons. The risk of convulsions may increase in patients taking tramadol and concomitant medication that can lower the seizure threshold (see section 4.5).

This medicinal product contains sucrose and therefore should not be used by patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency.

Precautions:

Zamadol SR prolonged-release hard capsules should be used with prudence in patients who have shown previous hypersensitivity to opiates, and in patients with severe renal or hepatic impairment, head injury, decreased level of consciousness, increased intracranial pressure, or patients in shock or at risk of convulsions.

At recommended therapeutic doses Zamadol SR prolonged-release hard capsules are unlikely to produce clinically relevant respiratory depression. Care should however be taken when administering Zamadol SR prolonged-release hard capsules to patients with existing respiratory depression or excessive bronchial secretion and in those patients taking concomitant CNS depressant drugs.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Patients treated with monoamine oxidase inhibitors within 14 days prior to the administration of the opioid pethidine have experienced life-threatening interactions affecting the central nervous system as well as the respiratory and circulatory centres. The possibility of similar interactions occurring between monoamine oxidase inhibitors and tramadol cannot be ruled out.

Tramadol may potentiate the CNS depressant effects of other centrally acting drugs (including alcohol) when administered concomitantly with such drugs.

Tramadol may increase the potential for selective serotonin re-uptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), anti-psychotics and other seizure threshold lowering drugs to cause convulsions (see section 4.4).

Isolated cases of serotonergic syndrome have been reported with the therapeutic use of tramadol in combination with other serotonergic agents such as selective serotonin re-uptake inhibitors (SSRIs). Serotonergic syndrome can be manifested by symptoms such as confusion, restlessness, fever, sweat, ataxia, hyperreflexia, myoclonia and diarrhoea. Withdrawal of the serotonergic agent produces a rapid improvement.

Administration of Zamadol SR prolonged-release hard capsules together with carbamazepine results in markedly decreased serum concentrations of tramadol which may reduce analgesic effectiveness and shorten the duration of action.

Caution should be exercised during concomitant treatment with tramadol and coumarin derivatives (e.g. warfarin) due to reports of increased INR and ecchymoses in some patients.

The combination of mixed agonists/antagonists (e.g. buprenorphine, nalbuphine, pentazocine) and tramadol is not recommended because it is theoretically possible that the analgesic effect of a pure agonist is attenuated under these circumstances.

The analgesic effect of tramadol is in part mediated by inhibition of the re-uptake of norepinephrine and enhancement of the release of serotonin (5-HT). In studies the pre- or postoperative application of the antiemetic 5-HT3 antagonist ondansetron increased the requirements of tramadol in patients with postoperative pain.

There is no interaction with food.

4.6 Pregnancy And Lactation

Pregnancy:

Zamadol SR prolonged-release hard capsules should not be used during pregnancy as there is inadequate evidence available to assess the safety of tramadol in pregnant women. Tramadol - administered before or during birth - does not affect uterine contractility. In neonates it may induce changes in the respiratory rate which are usually not clinically relevant.

Lactation:

Zamadol SR prolonged-release hard capsules should not be administered during breast feeding as tramadol and its metabolites have been detected in breast milk. 0.1% of the dose administered to the mother may be excreted in milk.

4.7 Effects On Ability To Drive And Use Machines

Zamadol SR prolonged-release hard capsules may cause drowsiness and this effect may be potentiated by alcohol, anti-histamines and other CNS depressants. If patients are affected they should be warned not to drive or operate machinery.

4.8 Undesirable Effects

The most commonly reported adverse drug reactions are nausea and dizziness, both occurring in more than 10% of patients.

Immune system disorders:

Rare (

Metabolism and nutrition disorders:

Rare (

Psychiatric disorders:

Rare (1/10,000 to < 1/1,000): psychic side-effects may occur following administration of tramadol which vary individually in intensity and nature (depending on personality and duration of medication). These include changes in mood (usually elation, occasionally dysphoria), changes in activity (usually suppression, occasionally increase) and changes in cognitive and sensorial capacity (e.g. decision behaviour, perception disorders), hallucinations, confusion, sleep disturbances and nightmares.

Prolonged administration of Zamadol SR prolonged-release hard capsules may lead to dependence (see section 4.4). Symptoms of withdrawal reactions, similar to those occurring during opiate withdrawal, may occur as follows: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal symptoms.

Nervous system disorders:

Very common (1/10) dizziness.

Common (

Rare (

Paraesthesia and tremor.

Very rare (< 1/10,000): vertigo

Eye disorders:

Rare (

Cardiac disorders:

Uncommon (1/1,000 to < 1/100): effects on cardiovascular regulation (palpitation, tachycardia, postural hypotension or cardiovascular collapse). These adverse effects may occur especially on intravenous administration and in patients who are physically stressed.

Rare (1/10,000 to < 1/1,000): bradycardia, increase in blood pressure.

Vascular disorders:

Very rare (< 1/10,000): flushing.

Respiratory disorders:

Worsening of asthma has also been reported, though a causal relationship has not been established.

Respiratory depression has been reported. If the recommended doses are considerably exceeded and other centrally depressant substances are administered concomitantly (see section 4.5 "Interaction with other medicinal products and other forms of interaction") respiratory depression may occur.

Gastrointestinal disorders:

Very common (1/10): vomiting, nausea.

Common (1/100 to < 1/10): constipation, dry mouth.

Uncommon (1/1,000 to < 1/100): retching, gastrointestinal irritation (a feeling of pressure in the stomach, bloating).

Hepatobiliary disorders:

In a few isolated cases an increase in liver enzyme values has been reported in a temporal connection with the therapeutic use of tramadol.

Skin and subcutaneous tissue disorders:

Common (1/100 to < 1/10): sweating.

Uncommon (1/1,000 to < 1/100): dermal reactions (e.g. pruritus, rash, urticaria).

Musculoskeletal, connective tissue and bone disorders:

Rare (1/10,000 to < 1/1,000): motorial weakness.

Renal and urinary system disorders:

Rare (1/10,000 to < 1/1,000): micturition disorders (difficulty in passing urine and urinary retention).

General disorders:

Common (

4.9 Overdose

Symptoms of tramadol overdose include vomiting, miosis, sedation, seizures, respiratory depression and hypotension, with circulatory failure and coma. Respiratory failure may also occur. Such symptoms are typical of opioid analgesics.

Treatment of overdose requires the maintenance of the airway and cardiovascular functions. Respiratory depression may be reversed using naloxone and fits controlled with diazepam. Naloxone administration may increase the risk of seizures.

The treatment of acute overdose of tramadol using haemodialysis or haemofiltration alone is not sufficient or suitable due to the slow elimination of tramadol from the serum by these routes.

5. Pharmacological Properties 5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Other opioids, ATC code: N02AX02

Tramadol is a centrally acting analgesic which possesses opioid agonist properties. Tramadol consists of two enantiomers, the (+)-isomer is predominantly active as an opioid with preferential activity for the ?-receptor. The (-)-isomer potentiates the analgesic effect of the (+)-isomer and is active as an inhibitor of noradrenaline and serotoninuptake thereby modifying the transmission of pain impulses.

Tramadol also has an antitussive action. At the recommended dosages, the effects of tramadol given orally on the respiratory and cardiovascular systems appear to be clinically insignificant. The potency of tramadol is reported to be 1/10 to 1/6 of morphine.

5.2 Pharmacokinetic Properties

About 90% of tramadol released from Zamadol SR prolonged-release hard capsules is absorbed after oral administration. The mean absolute bioavailability is approximately 70%, irrespective of concomitant intake of food.

The difference between absorbed and non-metabolised available tramadol is probably due to low first-pass effect. The first pass-effect after oral administration is a maximum of 30%.

Tramadol has a high tissue affinity with an apparent volume of distribution of 203 ± 40 litres after oral dosing in healthy volunteers. Protein binding is limited to 20%.

After single dose administration of Zamadol SR 50 mg prolonged-release hard capsules the peak plasma concentration Cmax 70 ± 16 ng/ml is reached after 5.3 h. After administration of Zamadol SR 100 mg prolonged-release hard capsules Cmax 137 ± 27 ng/ml is reached after 5.9 h. Following administration of Zamadol SR 200 mg prolonged-release hard capsules Cmax 294 ± 82 ng/ml is reached after 6.5 h. The reference product (Tramadol Immediate Release Capsules, given as a total dose of 200 mg tramadol hydrochloride) reached a peak concentration of Cmax 640 ± 143 ng/ml after 2.0 hours.

The relative bioavailability for the slow release formulation after single dose administration is 89% and increases to 100% after multiple dose administration in comparison to the reference product.

Tramadol passes the blood-brain and placenta barriers. Very small amounts of the substance and its O-demethyl derivative are found in the breast-milk (0.1% and 0.02% respectively of the applied dose).

Elimination of half-life t??is approximately 6 h, irrespective of the mode of administration. In patients above 75 years of age it may be prolonged by a factor of 1.4.

In humans tramadol is mainly metabolised by means of N- and O-demethylation and conjugation of the O-demethylation products with glucuronic acid. Only O-desmethyltramadol is pharmacologically active. There are considerable interindividual quantitative differences between the other metabolites. So far, eleven metabolites have been found in the urine. Animal experiments have shown that O-desmethyltramadol is more potent than the parent substance by the factor 2-4. Its half life t?? (6 healthy volunteers) is 7.9 h (range 5.4-9.6 h) and is approximately that of tramadol.

The inhibition of one or both cytochrome P450 isoenzymes, CYP3A4 and CYP2D6 involved in the metabolism of tramadol, may affect the plasma concentration of tramadol or its active metabolite. The clinical consequences of any such interactions are not known.

Tramadol and its metabolites are almost completely excreted via the kidneys. Cumulative urinary excretion is 90% of the total radioactivity of the administered dose. In cases of impaired hepatic and renal function the half-life may be slightly prolonged. In patients with cirrhosis of the liver, elimination half-lives of 13.3 ± 4.9 h (tramadol) and 18.5 ± 9.4 h (O-desmethyltramadol), in an extreme case 22.3 h and 36 h respectively have been determined. In patients with renal insufficiency (creatinine clearance < 5 ml/min) the values were 11 ± 3.2 h and 16.9 ± 3 h, in an extreme case 19.5 h and 43.2 h, respectively.

Tramadol has a linear pharmacokinetic profile within the therapeutic dosage range.

The relationship between serum concentrations and the analgesic effect is dose-dependent, but varies considerably in isolated cases. A serum concentration of 100 - 300 ng/ml is usually effective.

5.3 Preclinical Safety Data

Pre-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential. Studies of tramadol in rats and rabbits have revealed no teratogenic effects. However, embryo toxicity was shown in the form of delayed ossification. Fertility, reproductive performance and development of offspring were unaffected.

6. Pharmaceutical Particulars 6.1 List Of Excipients

Capsule Contents: Sugar spheres (sucrose and maize starch), colloidal anhydrous silica, ethylcellulose, shellac, talc.

Capsule Shell: Gelatin, Titanium Dioxide (E171)

The 50 mg and 150 mg capsules also contain Iron Oxide Yellow (E172) and Indigotine (E132).

The 200 mg capsules also contain Iron Oxide Yellow (E172)

Printing ink contains shellac, iron oxide black (E172) and propylene glycol.

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

3 years.

6.4 Special Precautions For Storage

Do not store above 25°C. Store in the original package in order to protect from moisture.

6.5 Nature And Contents Of Container

White opaque PVC/PVDC and aluminium foil blisters. Each blister contains 10 capsules.

Each pack contains 10, 20, 30, 50, 60 or 100 capsules per pack.

Not all pack sizes may be marketed in all Member States.

6.6 Special Precautions For Disposal And Other Handling

No special requirements.

7. Marketing Authorisation Holder

Meda Pharmaceuticals Ltd

Skyway House

Parsonage Road

Takeley

Bishop's Stortford

CM22 6PU

UK

8. Marketing Authorisation Number(S)

PL 15142/0120

PL 15142/0121

PL 15142/0122

PL 15142/0123

9. Date Of First Authorisation/Renewal Of The Authorisation

September 2007

10. Date Of Revision Of The Text

10 September 2009


read more / Download


Phendimetrazine Sustained-Release Capsules


Pronunciation: fen-dye-MEH-trah-zeen
Generic Name: Phendimetrazine
Brand Name: Examples include Bontril SR and Prelu-2 TR
Phendimetrazine Sustained-Release Capsules are used for:

The short-term management of obesity combined with a diet and exercise program.

Phendimetrazine Sustained-Release Capsules are an anorectic. Exactly how Phendimetrazine Sustained-Release Capsules works is unknown, although one of its effects is to decrease your appetite.

Do NOT use Phendimetrazine Sustained-Release Capsules if: you are allergic to any ingredient in Phendimetrazine Sustained-Release Capsules you have heart disease, glaucoma, an overactive thyroid, severe or uncontrolled high blood pressure, are highly nervous or agitated, or have a history of drug abuse you are taking guanadrel or guanethidine, or if you have taken furazolidone or a monoamine oxidase (MAO) inhibitor (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Phendimetrazine Sustained-Release Capsules:

Some medical conditions may interact with Phendimetrazine Sustained-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement if you have allergies to medicines, foods, or other substances if you have diabetes or high blood pressure

Some MEDICINES MAY INTERACT with Phendimetrazine Sustained-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:

Furazolidone, monoamine oxidase (MAO) inhibitors (eg, phenelzine), selective serotonin reuptake inhibitor (SSRI), or tramadol because the risk of severe high blood pressure, irregular heartbeat, high fever, tremors, and seizures may be increased Guanadrel or guanethidine because effectiveness may be decreased by Phendimetrazine Sustained-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Phendimetrazine Sustained-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Phendimetrazine Sustained-Release Capsules:

Use Phendimetrazine Sustained-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take Phendimetrazine Sustained-Release Capsules about 1 hour before the morning meal. Swallow Phendimetrazine Sustained-Release Capsules whole. Do not break, crush, or chew before swallowing. If you miss a dose of Phendimetrazine Sustained-Release Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Phendimetrazine Sustained-Release Capsules.

Important safety information: Phendimetrazine Sustained-Release Capsules may cause dizziness or blurred vision. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Phendimetrazine Sustained-Release Capsules. Using Phendimetrazine Sustained-Release Capsules alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks. Diabetes patients - Phendimetrazine Sustained-Release Capsules may affect your blood sugar. Check blood sugar levels closely and ask your doctor before adjusting the dose of your diabetes medicine. Before you have any medical or dental treatments, emergency care, or surgery, tell the doctor or dentist that you are using Phendimetrazine Sustained-Release Capsules. Phendimetrazine Sustained-Release Capsules are not recommended for use in CHILDREN younger than 12 years of age. Safety and effectiveness in this age group have not been confirmed. PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Phendimetrazine Sustained-Release Capsules, discuss with your doctor the benefits and risks of using Phendimetrazine Sustained-Release Capsules during pregnancy. It is unknown if Phendimetrazine Sustained-Release Capsules are excreted in breast milk. If you are or will be breast-feeding while you are using Phendimetrazine Sustained-Release Capsules, check with your doctor or pharmacist to discuss the risks to your baby.

When used for long periods of time or at high doses, Phendimetrazine Sustained-Release Capsules may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Phendimetrazine Sustained-Release Capsules stops working well. Do not take more than prescribed.

When used for longer than a few weeks or at high doses, some people develop a need to continue taking Phendimetrazine Sustained-Release Capsules. This is known as DEPENDENCE or addiction.

If you suddenly stop taking Phendimetrazine Sustained-Release Capsules, you may experience WITHDRAWAL symptoms including extreme fatigue and depression.

Possible side effects of Phendimetrazine Sustained-Release Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Agitation; blurred vision; constipation; diarrhea; dizziness; dry mouth; flushing; headache; nausea; nervousness; overstimulation; restlessness; trouble sleeping

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); changes in sex drive; fast or irregular heartbeat; frequent urination or trouble urinating; hallucinations; seizures; severe headache or dizziness; stomach pain; sweating; tremor; unusual behavior or personality changes

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Phendimetrazine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coma; confusion; diarrhea; nausea; panic attack; rapid breathing; seizures; severe restlessness; stomach cramps; tremor; vomiting.

Proper storage of Phendimetrazine Sustained-Release Capsules:

Store Phendimetrazine Sustained-Release Capsules at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Phendimetrazine Sustained-Release Capsules out of the reach of children and away from pets.

General information: If you have any questions about Phendimetrazine Sustained-Release Capsules, please talk with your doctor, pharmacist, or other health care provider. Phendimetrazine Sustained-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people. If your symptoms do not improve or if they become worse, check with your doctor. Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Phendimetrazine Sustained-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012 Database Edition 12.1.1.002 Copyright © 2012 Wolters Kluwer Health, Inc. More Phendimetrazine resources Phendimetrazine Side Effects (in more detail) Phendimetrazine Use in Pregnancy & Breastfeeding Drug Images Phendimetrazine Drug Interactions Phendimetrazine Support Group 87 Reviews for Phendimetrazine - Add your own review/rating Compare Phendimetrazine with other medications Obesity
read more / Download


Vulvodynia Medications


Definition of Vulvodynia: Vulvodynia is described as chronic vulvar discomfort with complaints of burning and superficial irritation.

Drugs associated with Vulvodynia

The following drugs and medications are in some way related to, or used in the treatment of Vulvodynia. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.


Drug List: Aventyl Carbatrol-Sustained-Release-Capsules Effexor-Xr-Extended-Release-Capsules Elavil Epitol Fanatrex Gabarone Lexapro Neurontin Norpramin Pamelor Prozac Prozac-Weekly-Delayed-Release-Capsules Rapiflux Tegretol Tegretol-Xr-Sustained-Release-Tablets Topamax Topamax-Sprinkle Topiragen Vanatrip
read more / Download


Cyclobenzaprine Extended-Release Capsules


Pronunciation: SYE-kloe-BEN-za-preen
Generic Name: Cyclobenzaprine
Brand Name: Amrix
Cyclobenzaprine Extended-Release Capsules are used for:

Treating muscle spasms caused by painful muscle conditions. It should be used along with rest and physical therapy. It may also be used for other conditions as determined by your doctor.

Cyclobenzaprine Extended-Release Capsules are a muscle relaxant. It works in parts of the brain and nervous system to help reduce muscle spasms.

Do NOT use Cyclobenzaprine Extended-Release Capsules if: you are allergic to any ingredient in Cyclobenzaprine Extended-Release Capsules you have an overactive thyroid, liver problems, or certain heart problems (eg, irregular heartbeat, congestive heart failure, heart block, conduction problems), or if you have recently had a heart attack you are taking or have taken a monoamine oxidase inhibitor (MAOI) (eg, phenelzine, rasagiline) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Cyclobenzaprine Extended-Release Capsules:

Some medical conditions may interact with Cyclobenzaprine Extended-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement if you have allergies to medicines, foods, or other substances if you have a history of liver problems, heart problems, cerebral palsy, brain or spinal cord disease, or stroke if you have a history of glaucoma, increased pressure in the eye, or trouble urinating

Some MEDICINES MAY INTERACT with Cyclobenzaprine Extended-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:

MAOIs (eg, phenelzine, rasagiline) because serious, sometimes fatal reactions, including high fever and severe seizures, may occur Tramadol because the risk of seizures may be increased Droperidol or fluoxetine because severe heart problems, including irregular heartbeat, may occur Anticholinergics (eg, methscopolamine, benztropine), barbiturates (eg, phenobarbital), cimetidine, fluconazole, fluvoxamine, mibefradil, naproxen, or phenothiazines (eg, chlorpromazine) because they may increase the risk of Cyclobenzaprine Extended-Release Capsules's side effects Carbamazepine because it may decrease Cyclobenzaprine Extended-Release Capsules's effectiveness or increase the risk of Cyclobenzaprine Extended-Release Capsules's side effects Guanethidine or guanfacine because their effectiveness may be decreased by Cyclobenzaprine Extended-Release Capsules Sympathomimetics (eg, albuterol, epinephrine, phenylephrine) because their effectiveness may be decreased or the risk of their side effects may be increased by Cyclobenzaprine Extended-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Cyclobenzaprine Extended-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Cyclobenzaprine Extended-Release Capsules:

Use Cyclobenzaprine Extended-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take Cyclobenzaprine Extended-Release Capsules by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation. Swallow Cyclobenzaprine Extended-Release Capsules whole. Do not break, crush, or chew before swallowing. Cyclobenzaprine Extended-Release Capsules works best if it is taken at the same time each day. Do not suddenly stop taking Cyclobenzaprine Extended-Release Capsules without checking with your doctor. If you miss a dose of Cyclobenzaprine Extended-Release Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Cyclobenzaprine Extended-Release Capsules.

Important safety information: Cyclobenzaprine Extended-Release Capsules may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Cyclobenzaprine Extended-Release Capsules with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it. Talk with your doctor before you drink alcohol or use medicines that may cause drowsiness (eg, sleep aids, muscle relaxers) while you are using Cyclobenzaprine Extended-Release Capsules; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness. Do NOT take more than the recommended dose or use for longer than 2 to 3 weeks without checking with your doctor. If your symptoms (eg, pain, tenderness, decreased range of motion) do not get better within 2 to 3 weeks or if they get worse, contact your doctor. Do not become overheated in hot weather or while you are being active; heatstroke may occur. If you experience dry mouth, use sugarless candy or gum, or melt bits of ice in your mouth. If dry mouth continues for more than 2 weeks, contact your dentist or doctor. Use of Cyclobenzaprine Extended-Release Capsules are not recommended in the ELDERLY; they may be more sensitive to its effects. Cyclobenzaprine Extended-Release Capsules has not been approved for use in CHILDREN; safety and effectiveness in children have not been confirmed. PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Cyclobenzaprine Extended-Release Capsules while you are pregnant. It is not known if Cyclobenzaprine Extended-Release Capsules are found in breast milk. If you are or will be breast-feeding while you use Cyclobenzaprine Extended-Release Capsules, check with your doctor. Discuss any possible risks to your baby. Possible side effects of Cyclobenzaprine Extended-Release Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Constipation; dizziness; drowsiness; dry mouth; fatigue; nausea; stomach pain or upset.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; fainting; fast or irregular heartbeat; mental or mood changes; numbness of an arm or a leg; one-sided weakness; seizures; severe dizziness or vomiting; speech or vision problems; sudden severe stomach pain; trouble urinating; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Cyclobenzaprine side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include agitation; chest pain; coma; confusion; fast or irregular heartbeat; hallucinations; loss of coordination; seizures; severe drowsiness, dizziness, or nausea; slurred speech; tremor; vomiting.

Proper storage of Cyclobenzaprine Extended-Release Capsules:

Store Cyclobenzaprine Extended-Release Capsules at 77 degrees F (25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Cyclobenzaprine Extended-Release Capsules out of the reach of children and away from pets.

General information: If you have any questions about Cyclobenzaprine Extended-Release Capsules, please talk with your doctor, pharmacist, or other health care provider. Cyclobenzaprine Extended-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people. If your symptoms do not improve or if they become worse, check with your doctor. Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Cyclobenzaprine Extended-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012 Database Edition 12.1.1.002 Copyright © 2012 Wolters Kluwer Health, Inc. More Cyclobenzaprine resources Cyclobenzaprine Side Effects (in more detail) Cyclobenzaprine Dosage Cyclobenzaprine Use in Pregnancy & Breastfeeding Drug Images Cyclobenzaprine Drug Interactions Cyclobenzaprine Support Group 169 Reviews for Cyclobenzaprine - Add your own review/rating Compare Cyclobenzaprine with other medications Fibromyalgia Migraine Muscle Spasm Sciatica Temporomandibular Joint Disorder
read more / Download


Fibromyalgia Medications


Drugs associated with Fibromyalgia

The following drugs and medications are in some way related to, or used in the treatment of Fibromyalgia. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Fibromyalgia Epicondylitis, Tennis Elbow (17 drugs) Learn more about Fibromyalgia

Medical Encyclopedia:

Fibromyalgia

Harvard Health Guide:

Symptoms and treatment for Fibromyalgia

Drugs.com Health Center:

Fibromyalgia
Drug List: 5-Htp Amibid-La Amrix-Extended-Release-Capsules Comfort-Pac-With-Cyclobenzaprine Cymbalta Deltasone Desyrel Desyrel-Dividose Effexor Effexor-Xr-Extended-Release-Capsules Elavil Fanatrex Fexmid Flexeril Gabarone Ganidin-Nr Gg-200-Nr Guaifenesin-La Guaifenex-G Guaifenex-La Lexapro Lyrica Meticorten Mobic Mucinex Muco-Fen-1200 Neurontin Nuvigil Organidin-Nr-Immediate-Release-Capsules Pristiq Prozac Prozac-Weekly-Delayed-Release-Capsules Q-Bid-La Rapiflux Revia Savella Skelaxin Sterapred Sterapred-Ds Strattera Topamax Topamax-Sprinkle Topiragen Vanatrip Xyrem
read more / Download


Calcium channel blocking agents


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Calcium channel blockers block voltage gated calcium channels and inhibits the influx of calcium ions into cardiac and smooth muscle cells. The decrease in intracellular calcium reduces the strength of heart muscle contraction, reduces conduction of impulses in the heart, and causes vasodilatation.

Decrease in intracellular calcium in the heart decreases cardiac contractility. Decreased calcium in the vascular smooth muscle reduces its contraction and therefore causes vasodilatation.

Decrease in cardiac contractility decreases cardiac output and vasodilatation decreases total peripheral resistance, both of which cause a drop in blood pressure.

Calcium channel blocking agents are used to treat hypertension.

See also

Medical conditions associated with calcium channel blocking agents:

Angina Angina Pectoris Prophylaxis Arrhythmia Atrial Fibrillation Atrial Flutter Bipolar Disorder Cluster Headaches Coronary Artery Disease Heart Failure High Blood Pressure Hypertensive Emergency Hypertrophic Cardiomyopathy Idiopathic Hypertrophic Subaortic Stenosis Ischemic Stroke Migraine Prevention Nocturnal Leg Cramps Premature Labor Raynaud's Syndrome Subarachnoid Hemorrhage Supraventricular Tachycardia Drug List: Afeditab-Cr Diltia-Xt-24-Hour-Sustained-Release-Capsules Diltiazem-Hydrochloride-Sr Nimotop Adalat Cartia-Xt-24-Hour-Sustained-Release-Beads-Capsules Calan-Sr-Controlled-Release-Tablets Cardizem Isoptin-Sr-Controlled-Release-Tablets Nifediac-Cc Tiazac Verelan-Pm-Sustained-Release-Capsules-Controlled-Onset Diltiazem-Hydrochloride-Cd Procardia Adalat-Cc-Sustained-Release-Tablets Calan Cardizem-La-24-Hour-Extended-Release-Beads-Tablets Procardia-Xl-Sustained-Release-Tablets Isoptin Nifedical-Xl Cardizem-Cd-24-Hour-Sustained-Release-Beads-Capsules Norvasc Plendil Dynacirc-Cr-Extended-Release-Tablets Verelan-Sustained-Release-Pellet-Filled-Capsules Taztia-Xt-24-Hour-Extended-Release-Beads-Capsules Cardene Cardene-Iv Cardene-Sr-Sustained-Release-Capsules Cleviprex Covera-Hs-Sustained-Release-Tablets-Controlled-Onset Dilacor-Xr-24-Hour-Sustained-Release-Capsules Dilt-Xr-24-Hour-Sustained-Release-Capsules Diltiazem-Hydrochloride-Xr Diltiazem-Hydrochloride-Xt Diltzac Dynacirc Matzim-La Sular-Extended-Release-Tablets Vascor
read more / Download


Migraine Prevention (Migraine Prophylaxis) Medications



Hydrocephalus Medications


Definition of Hydrocephalus: Hydrocephalus is an accumulation of cerebrospinal fluid in the ventricles of the brain, leading to their enlargement and swelling.

Drugs associated with Hydrocephalus

The following drugs and medications are in some way related to, or used in the treatment of Hydrocephalus. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Hydrocephalus

Micromedex Care Notes:

Hydrocephalus Hydrocephalus In Children

Medical Encyclopedia:

Hydrocephalus

Harvard Health Guide:

Symptoms and treatment for Hydrocephalus
Drug List: Diamox Diamox-Sequels-Sustained-Release-Capsules
read more / Download


Cevi-Bid Controlled-Release Capsules


Pronunciation: a-SKOR-bik AS-id
Generic Name: Ascorbic Acid
Brand Name: Examples include Cemill and Cevi-Bid
Cevi-Bid Controlled-Release Capsules are used for:

Treating and preventing low levels of vitamin C. It may also be used for other conditions as determined by your doctor.

Cevi-Bid Controlled-Release Capsules are a vitamin. It works by supplementing vitamin C, which is used in many functions in the body.

Do NOT use Cevi-Bid Controlled-Release Capsules if: you are allergic to any ingredient in Cevi-Bid Controlled-Release Capsules

Contact your doctor or health care provider right away if any of these apply to you.

Before using Cevi-Bid Controlled-Release Capsules:

Some medical conditions may interact with Cevi-Bid Controlled-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement if you have allergies to medicines, foods, or other substances if you have diabetes, glucose-6-phosphate dehydrogenase deficiency, a high iron level in the blood, anemia (eg, sickle cell, sideroblastic, thalassemia), or kidney stones

Some MEDICINES MAY INTERACT with Cevi-Bid Controlled-Release Capsules. Tell your health care provider if you are taking any other medicines, especially any of the following:

Anticoagulants (eg, warfarin) because side effects may be increased by Cevi-Bid Controlled-Release Capsules

This may not be a complete list of all interactions that may occur. Ask your health care provider if Cevi-Bid Controlled-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Cevi-Bid Controlled-Release Capsules:

Use Cevi-Bid Controlled-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Cevi-Bid Controlled-Release Capsules may be taken with or without food. Swallow Cevi-Bid Controlled-Release Capsules whole. Do not break, crush, or chew before swallowing. Take Cevi-Bid Controlled-Release Capsules with a full glass of water (8 oz/240 mL). Do not lie down for 30 minutes after taking Cevi-Bid Controlled-Release Capsules. If you miss a dose of Cevi-Bid Controlled-Release Capsules, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Cevi-Bid Controlled-Release Capsules.

Important safety information: Do not take large doses of vitamins (megadoses or megavitamin therapy) while taking Cevi-Bid Controlled-Release Capsules unless directed to by your doctor. Cevi-Bid Controlled-Release Capsules may cause incorrect results with some in-home cholesterol test kits. Check with your doctor or pharmacist if you are taking Cevi-Bid Controlled-Release Capsules and need to check your cholesterol at home. Diabetes patients - Cevi-Bid Controlled-Release Capsules may cause incorrect test results with some urine glucose tests. Check with your doctor before you adjust the dose of your diabetes medicine or change your diet. Cevi-Bid Controlled-Release Capsules may cause incorrect test results with kits used to check for blood in the stool. Check with your doctor if you are taking Cevi-Bid Controlled-Release Capsules when using the test kit. PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Cevi-Bid Controlled-Release Capsules, discuss with your doctor the benefits and risks of using Cevi-Bid Controlled-Release Capsules during pregnancy. Cevi-Bid Controlled-Release Capsules are excreted in breast milk. If you are or will be breast-feeding while you are using Cevi-Bid Controlled-Release Capsules, check with your doctor or pharmacist to discuss the risks to your baby. Possible side effects of Cevi-Bid Controlled-Release Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Diarrhea; nausea; upset stomach; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); kidney stones (eg, abdominal pain/back pain, painful urination).

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Cevi-Bid side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include gout.

Proper storage of Cevi-Bid Controlled-Release Capsules:

Store Cevi-Bid Controlled-Release Capsules at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Cevi-Bid Controlled-Release Capsules out of the reach of children and away from pets.

General information: If you have any questions about Cevi-Bid Controlled-Release Capsules, please talk with your doctor, pharmacist, or other health care provider. Cevi-Bid Controlled-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people. If your symptoms do not improve or if they become worse, check with your doctor. Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Cevi-Bid Controlled-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012 Database Edition 12.1.1.002 Copyright © 2012 Wolters Kluwer Health, Inc. More Cevi-Bid resources Cevi-Bid Side Effects (in more detail) Cevi-Bid Use in Pregnancy & Breastfeeding Cevi-Bid Drug Interactions Cevi-Bid Support Group 0 Reviews for Cevi-Bid - Add your own review/rating Compare Cevi-Bid with other medications Dietary Supplementation Scurvy Urinary Acidification
read more / Download


Proton pump inhibitors


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Proton pump inhibitors act by irreversible inhibition of the H+/K+ ATPase, in the parietal cells of the stomach. It markedly inhibits gastric acid secretion and has a long duration of action. They are used for treatment of gastric and duodenal ulcers, gastroesophageal reflux disease and other excessive gastrointestinal acid secretory disorders.

See also

Medical conditions associated with proton pump inhibitors:

Aspiration PneumoniaBarrett's EsophagusDuodenal UlcerDuodenal Ulcer ProphylaxisErosive EsophagitisGastrointestinal HemorrhageGERDHelicobacter Pylori InfectionIndigestionMultiple Endocrine AdenomasNSAID-Induced Gastric UlcerNSAID-Induced Ulcer ProphylaxisPathological Hypersecretory ConditionsPeptic UlcerStomach UlcerStress Ulcer ProphylaxisSystemic MastocytosisZollinger-Ellison Syndrome Drug List:/tags/zegerid/
/tags/nexium_iv/
/tags/prevacid/
/tags/kapidex/
/tags/prilosec/
/tags/prevacid-solutab-orally-disintegrating-tablets/
/tags/prevacid-i-v/
Protonix-I-V
read more / Download


Bartter Syndrome Medications


Definition of Bartter Syndrome: Bartter syndrome refers to a rare group of conditions that affect the kidneys. People with Bartter syndrome have a loss of potassium (hypokalemic alkalosis) and a rise in the hormone aldosterone.

Drugs associated with Bartter Syndrome

The following drugs and medications are in some way related to, or used in the treatment of Bartter Syndrome. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Topics under Bartter Syndrome Gitelman Syndrome (3 drugs) Learn more about Bartter Syndrome

Medical Encyclopedia:

Bartter syndrome
Drug List: Indocin Indocin-Iv Indocin-Sr-Sustained-Release-Capsules
read more / Download


ZAMADOL 24hr 150 (200 / 300 / 400)mg TABLETS


1. Name Of The Medicinal Product

ZAMADOL 24hr 150 (200/300/400) mg prolonged release tablets.

2. Qualitative And Quantitative Composition

Each tablet contains 150 (200/300/400) mg of tramadol hydrochloride

Excipient: Each prolonged-release tablet contains 0.60 (1.00/1.40/1.80) mg lactose monohydrate (see section 4.4).

For a full list of excipients, see section 6.1.

3. Pharmaceutical Form

Prolonged release tablet

White film coated tablets marked T 150 (200/300/400)

4. Clinical Particulars 4.1 Therapeutic Indications

Treatment of moderate to severe pain.

4.2 Posology And Method Of Administration

ZAMADOL 24hr tablets should be taken at 24-hourly intervals and must be swallowed whole and not chewed.

As with all analgesic drugs, the dose of tramadol should be adjusted according to the severity of the pain and the clinical response of the individual patient. The correct dosage for any individual patient is that which controls the pain with no or tolerable side effects for a full 24 hours. Patients transferring from immediate release tramadol preparations should have their total daily dose calculated, and start on the nearest dose in the ZAMADOL 24hr range. It is recommended that patients are slowly titrated to higher doses to minimise transient side effects. The need for continued treatment should be assessed at regular intervals as withdrawal symptoms and dependence have been reported. (See Section 4.4 Special Warnings and Precautions for Use).A total daily dose of 400 mg should not be exceeded except in special clinical circumstances.

Adults and children over 12 years: The usual initial dose is one 150 mg tablet daily. If pain relief is not achieved, the dosage should be titrated upwards until pain relief is achieved.

Elderly patients: Dosing as for adults. The elimination half-life of tramadol may be prolonged in patients over 75 years . A starting dose of 150 mg daily is recommended. Dose titration upwards should be carefully monitored.

Patients with renal or hepatic insufficiency: The elimination half-life of tramadol may be prolonged in these patient populations. A starting dose of 150 mg daily is recommended. Dose titration upwards should be carefully monitored. Tramadol is not recommended for patients with severe renal impairment and/or severe hepatic impairment.

As tramadol is only removed very slowly by haemodialysis or by haemofiltration, post-dialysis administration to maintain analgesia is not usually necessary.

Children under 12 years: ZAMADOL 24hr has not been studied in children. Safety and efficacy of ZAMADOL 24hr have not been established and the product should not be used in children.

4.3 Contraindications

Hypersensitivity to tramadol or to any of the excipients; acute intoxication with alcohol, hypnotics, centrally acting analgesics, opioids or psychotropic drugs. Tramadol should not be administered to patients who are receiving monoamine oxidase inhibitors or within two weeks of their withdrawal.

Tramadol must not be used for narcotic withdrawal treatment.

4.4 Special Warnings And Precautions For Use

Warnings

At therapeutic doses withdrawal symptoms have been reported at a frequency of 1 in 8,000. Reports of dependence and abuse have been less frequent. Because of this potential the clinical need for continued analgesic treatment should be reviewed regularly.

In patients with a tendency to drug abuse or dependence, treatment should be for short periods and under strict medical supervision.

Tramadol is not suitable as a substitute in opioid-dependent patients. Although it is an opioid agonist, tramadol cannot suppress morphine withdrawal symptoms.

Precautions

Convulsions have been reported at therapeutic doses and the risk may be increased at doses exceeding the usual upper daily dose limit. Patients with a history of epilepsy or those susceptible to seizures should only be treated with tramadol if there are compelling reasons. The risk of convulsions may increase in patients taking tramadol and concomitant medication that can lower the seizure threshold. (See Section 4.5 Interactions with other Medicaments and other forms of Interaction).

Tramadol should be used with caution in patients with head injury, increased intracranial pressure, severe impairment of hepatic and renal function and in patients prone to convulsive disorders or in shock.

Care should be taken when treating patients with respiratory depression, or if concomitant CNS depressant drugs are being administered, as the possibility of respiratory depression cannot be excluded in these situations. At therapeutic doses respiratory depression has infrequently been reported.

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction

Concurrent administration of tramadol with other centrally acting drugs, including alcohol, may potentiate CNS depressant effects.

Simultaneous treatment with carbamazepine may shorten the analgesic effect as a result of a reduction in serum levels of tramadol and its active metabolite.

Co-administration with cimetidine is associated with a small prolongation of the half-life of tramadol, but this is not clinically relevant.

Tramadol can induce convulsions and increase the potential for selective serotonin re-uptake inhibitors (SSRIs), tricyclic anti-depressants (TCAs), anti-psychotics and other seizure threshold lowering drugs to cause convulsions (see Section 4.4 Special Warnings and Special Precautions for Use and 5.2 Pharmacokinetic Properties). Co-administration with SSRIs may lead to an increase of 5HT associated effects.

Co-administered ritonavir may increase serum concentration of tramadol resulting in tramadol toxicity.

Digoxin toxicity has occurred rarely during co-administration of digoxin and tramadol.

MAO inhibitors: A serotoninergic syndrome is likely to occur: diarrhoea, tachycardia, sweating, tremor, confusion, coma. In case of recent treatment with MAOIs, treatment with tramadol should not be started until 15 days after cessation of treatment with MAOIs.

Other morphine derivatives (including anti-tussives, substitution treatments), benzodiazepines, barbiturates: Increased risk of respiratory depression, that may be fatal in overdosage.

Mixed agonists/antagonists (eg buprenorphine, nalbuphine, pentazocine): The analgesic effect of tramadol which is a pure agonist may be reduced, and a withdrawal syndrome may occur.

There have been isolated reports of interaction with coumarin anticoagulants resulting in an increased INR and so care should be taken when commencing treatment with tramadol in patients on anticoagulants.

The analgesic effect of tramadol is in part mediated by inhibition of the re-uptake of norepinephrine and enhancement of the release of serotonin (5-HT). In studies the pre- or postoperative application of the antiemetic 5-HT3 antagonist ondansetron increased the requirements of tramadol in patients with postoperative pain.

4.6 Pregnancy And Lactation

There are no adequate data from the use of tramadol in pregnant women. Animal studies have shown reproductive toxicity, but not teratogenic effects (see section 5.3). Tramadol crosses the placental barrier and chronic use during pregnancy can cause withdrawal symptoms in the new-born baby. Therefore, it should not be used during pregnancy.

Tramadol administered before or during birth does not affect uterine contractility. In neonates it may induce changes in respiratory rate which are not usually clinically relevant.

During lactation very small amounts of tramadol and its metabolites (approximately 0.1% of an intravenous dose) are found in human breast milk. Therefore tramadol should not be administered during breast feeding.

4.7 Effects On Ability To Drive And Use Machines

Tramadol may cause drowsiness, blurred vision and dizziness which may be enhanced by alcohol or other CNS depressants. If affected, the patient should not drive or operate machinery.

4.8 Undesirable Effects

The following frequency categories form the basis for classification of the undesirable effects:

Very common (

Common (

Uncommon (

Rare (

Very rare (<1/10,000) not known (cannot be estimated from the available data)

 

Very Common

Common

Uncommon

Rare

Very Rare

Immune system disorders

 

 

 

 

 

 

Hypersensitivity

Anaphylactic reaction

 

 

Psychiatric disorders

 

 

 

 

 

 

Hallucinations

Nightmare

Mood altered

Elevated mood

Dysphoria

Decreased activity

Illusion

Agitation

Anxiety

Nervousness

Insomnia

Nervous system disorders

Dizziness

 

 

Headache

Paraesthesia

Increased activity

Cognitive disorder

Sensory disturbance

Judgement impaired

Convulsion

Hyperkinesia

Tremor

Eye disorders

 

 

 

 

 

 

Blurred vision

 

 

Cardiac disorders

 

 

 

 

Palpitations

Tachycardia

Bradycardia

 

 

Vascular disorders

 

 

 

 

Orthostatic hypotension

Circulatory collapse

Hypertension

Flushing

 

 

Respiratory, thoracic and mediastinal disorders

 

 

 

 

 

 

Dyspnoea

Asthma

Respiratory depression

Bronchospasm

Wheezing

 

 

Gastro-intestinal disorders

Nausea

Vomiting

Dry mouth

Retching

Constipat-ion

Abdominal discomfort

Anorexia

Diarrhoea

Gastro-intestinal disorder

Hepatobiliary disorders

 

 

 

 

 

 

 

 

Hepatic enzyme increased

Skin and subcutaneous tissue disorders

 

 

Hyperhidrosis

Pruritus

Rash

Urticaria

Angioedema

 

 

Renal and urinary disorders

 

 

 

 

 

 

Micturition disorder

Dysuria

Urinary retention

 

 

Musculoskeletal and connective tissue disorders

 

 

 

 

 

 

Muscular weakness

 

 

General disorders and administration site conditions Investigations

 

 

 

 

 

 

 

 

Drug withdrawal syndrome

4.9 Overdose

Symptoms of overdosage are typical of other opioid analgesics, and include miosis, vomiting, cardiovascular collapse, sedation and coma, seizures and respiratory depression. In severe cases tramadol overdose may result in a fatal outcome.

Supportive measures such as maintaining the patency of the airway and maintaining cardiovascular function should be instituted; naloxone should be used to reverse respiratory depression; fits can be controlled with diazepam.

Tramadol is minimally eliminated from the serum by haemodialysis or haemofiltration. Therefore treatment of acute intoxication with tramadol with haemodialysis or haemofiltration alone is not suitable for detoxification.

Emptying the gastric contents is useful to remove any unabsorbed drug, particularly when a modified release formulation has been taken.

5. Pharmacological Properties

Pharmacotherapeutic group: N02A X02

5.1 Pharmacodynamic Properties

Tramadol is a centrally acting analgesic (N02A X02). It is a non selective pure agonist at mu, delta and kappa opioid receptors with a higher affinity for the mu receptor. Other mechanisms that may contribute to its analgesic effect are inhibition of neuronal re-uptake of noradrenaline and 5HT.

5.2 Pharmacokinetic Properties

Following oral administration of a single dose, tramadol is almost completely absorbed and the absolute bioavailability is approximately 70%. Tramadol is metabolised to O

Following administration of one ZAMADOL 24hr tablet 200 mg in the fasting state, a mean peak plasma concentration (Cmax) of 192 ng.ml-1 was attained. This was associated with a median tmax of 6 hours (range 4-8 hours). The availability of tramadol from the ZAMADOL 24hr tablet 200 mg was complete when compared with an immediate release tramadol solution 100 mg, after dose adjustment. In the presence of food, the availability and controlled release properties of ZAMADOL 24hr tablets were maintained, with no evidence of dose-dumping.

A single dose-proportionality study has confirmed a linear pharmacokinetic response (in relation to tramadol and O-desmethyltramadol) following administration of the 200 mg, 300 mg and 400 mg tablets. A steady state study has confirmed the dose adjusted bioequivalence of the 150 mg and 200 mg tablets administered once-daily. This study also confirmed that the ZAMADOL 24hr tablet 150 mg provided an equivalent peak concentration and extent of availability of tramadol to an immediate release capsule 50 mg administered 8-hourly. On this basis it is recommended that patients receiving immediate release tramadol should be transferred initially to the nearest daily dose of ZAMADOL 24hr tablets. It may be necessary to titrate the dose thereafter.

A further steady state study has demonstrated that immediate release tramadol tablets 50 mg, administered 6-hourly, provided plasma concentrations that were greater than would have been anticipated following administration of a single dose. This observation is consistent with a non-linear elimination of the drug substance. In contrast, the plasma concentrations from ZAMADOL 24hr tablet 200 mg administered once-daily were in line with single dose data, confirming that the controlled delivery of tramadol from ZAMADOL 24hr minimises the non-linearity associated with faster-releasing preparations. The more predictable plasma concentrations may lead to a more manageable dose titration process.

5.3 Preclinical Safety Data

Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential.

Studies in rats and rabbits have revealed no teratogenic effects. However, embryotoxicity was shown in the form of delayed ossification. Fertility, reproductive performance and development of offspring were unaffected.

6. Pharmaceutical Particulars 6.1 List Of Excipients

Tablet core

Hydrogenated vegetable oil

Talc

Magnesium stearate

Film coat

Lactose Monohydrate

Hypromellose (E464)

Titanium dioxide (E171)

Macrogol 4000

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

3 years

6.4 Special Precautions For Storage

Do not store above 30oC.

6.5 Nature And Contents Of Container

1) PVC blisters with aluminium backing foil (containing 2, 7, 10, 14, 15, 20, 28, 30, 50,56, 60 or 100 tablets).

2) Polypropylene containers with polyethylene lids (containing 2, 7, 10, 14, 15, 20, 28, 30, 50,56, 60 or 100 tablets).

Not all pack sizes may be marketed

6.6 Special Precautions For Disposal And Other Handling

None.

7. Marketing Authorisation Holder

Napp Pharmaceuticals Ltd

Cambridge Science Park

Milton Road

Cambridge CB4 0GW

UK

8. Marketing Authorisation Number(S)

PL 16950/0084 (85/86/87)

9. Date Of First Authorisation/Renewal Of The Authorisation

7 November 2001/19 June 2006

10. Date Of Revision Of The Text

August 2009


read more / Download


Nabilone 1mg Capsules


Nabilone 1 mg Capsules

(nabilone)

Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If you experience any side effect and this becomes serious, tell your doctor or pharmacist. In this leaflet: 1. What Nabilone is and what it is used for 2. Before you take Nabilone Capsules 3. How to take Nabilone Capsules 4. Possible side effects 5. How to store Nabilone Capsules 6. Further information What Nabilone Is And What It Is Used For

Nabilone is a medicine that helps to reduce nausea and vomiting caused by many anticancer medicines.

Nabilone is often used when other medicines have not helped your nausea or vomiting.

Nabilone is a man-made chemical known as a cannabinoid. It is not made from the Cannabis plant but it is similar to some marijuana extracts and can cause similar effects.

Before You Take Nabilone Capsules Do not take Nabilone If you are allergic (hypersensitive) to any of the other ingredients of Nabilone Capsules (these are listed in section 6, "Further Information"). If your nausea / vomiting is not due to anticancer treatment. If you are under 18 years. Nabilone is not meant for children. Take special care with Nabilone

It is best if you take Nabilone Capsules in hospital, as you may experience side effects.

Tell your doctor before you start treatment if you have any of the following problems or if you develop any of these during treatment:

Any liver problems. High blood pressure or any other heart problem. Any mental illness, for example depression or schizophrenia. Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

In particular, tell your doctor if you are taking any sleeping pills, pain killers or tranquillisers.

Taking Nabilone with alcohol

Do not drink alcohol while you are taking Nabilone.

Pregnancy and breast-feeding

Tell your doctor before you start treatment

If you are pregnant, if you think that you are pregnant, or if you intend to become pregnant. If you are breast-feeding or planning to breast-feed.

Your doctor will then decide if you can take this medicine.

Driving and using machines

Nabilone Capsules may cause side effects such as sleepiness, confusion, hallucinations, a feeling of dizziness or spinning, poor muscle co-ordination, problems with your sight and problems with concentration. These side effects may occur up to 3 days after taking Nabilone. This may affect your ability to drive and operate machinery. Do not drive or operate machinery if you experience any of these side effects.

How To Take Nabilone Capsules

Always take Nabilone exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure how to take it. Your doctor will usually start you on the lowest possible dose.

It is best if you take Nabilone Capsules in hospital, especially the first time that you take Nabilone. This is because you may experience side effects.

The hospital doctor or nurse may give you your first dose the night before you start chemotherapy and the second dose one to three hours before it begins.

Swallow the capsules with water.

Dose The usual dose is 1 or 2 capsules twice a day. You should never take more than 2 capsules three times a day. You can take Nabilone while you are having chemotherapy treatment and for up to 2 days after your last dose of chemotherapy.

The dosing recommendations for elderly patients are the same as for other adults.

If you take more Nabilone than you should

If you ever take too many capsules, tell your doctor or get someone to take you to the nearest hospital casualty department immediately together with your medicine to show to the doctor.

If you forget to take Nabilone

If you miss a dose, wait until it is time for the next dose, and then continue as before.

Do not take a double dose to make up for a forgotten dose.

Possible Side Effects

Like all medicines, Nabilone can cause side effects, although not everybody gets them.

Side effects that you may experience are: Feeling sleepy, relaxed, or "high". A few patients have had hallucinations, felt confused, depressed, anxious or had other changes in their mood or mental state. A feeling of dizziness or spinning, especially when you stand up. Poor muscle co-ordination. Dry mouth, problems with your sight or concentration, difficulty sleeping, or headaches. Shaking, a faster heart beat than normal, low blood pressure, losing your appetite and stomach pains.

Any changes in your mood, such as feeling depressed, relaxed or "high", may last for 2 or 3 days after you stop taking Nabilone. You may find that you get used to these feelings.

If you have any of these side effects, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How To Store Nabilone Capsules Keep Nabilone Capsules out of the reach and sight of children. Do not use Nabilone after the expiry date which is stated on the bottle and carton after "EXP". The expiry date refers to the last day of that month. Keep the container tightly closed. Store your capsules at room temperature (15-25°C) in a dry place. If your doctor tells you to stop taking the capsules, please take them back to the pharmacist. Medicines should not be disposed of via wastewater or household waste. Only keep the capsules if your doctor tells you to. Further Information What Nabilone contains

Active substance: Nabilone. Each capsule contains 1 mg of nabilone.
Other ingredients: Povidone, starch, gelatin and the colourants E132, E172 and E171.

What Nabilone looks like and contents of the pack Nabilone capsules are blue and white and have CL 3101 printed on them. Each bottle or blister pack of Nabilone contains 20 capsules. Marketing Authorisation Holder Meda Pharmaceuticals Ltd. Skyway House Parsonage Road Takeley Bishop's Stortford CM22 6PU UK Manufacturer Dales Pharmaceuticals Limited Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW UK

For any information about this medicine, please contact the Marketing Authorisation Holder.

This leaflet was last approved in July 2009.

F687


read more / Download


Methylxanthines


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

Methylxanthines act as bronchodilators by relaxing bronchial smooth muscle and helps the constricted airways to dilate. The exact mechanism of action with regards to methylxanthine causing bronchodilatation is not well understood but it appears that methylxanthines inhibit the enzyme phosphodiesterase, which degrades cyclic AMP, so methylxanthines tend to increase the concentration of cyclic AMP.

Methylxanthines are bronchodilators used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).

See also

Medical conditions associated with methylxanthines:

Apnea of Prematurity Asthma Asthma, acute Asthma, Maintenance Bronchitis COPD Drug List: Theo-24-Sustained-Release-Capsules Uniphyl-Sustained-Release-Tablets Theo-Dur Choledyl Choledyl-Sa Dilor Dilor-400 Dylix-Elixir Elixophyllin-Elixir Lufyllin Lufyllin-400 Neothylline Phyllocontin Quibron-T Quibron-T-Sr Theo-Time Theocap-Sustained-Release-Capsules Theochron-Sustained-Release-Tablets Theolair-Tablets Truphylline Truxophyllin
read more / Download


Carbetapentane/Guaifenesin Sustained-Release Capsules


Pronunciation: car-bay-ta-PEN-tane/gwye-FEN-eh-sin
Generic Name: Carbetapentane/Guaifenesin
Brand Name: Dynex VR
Carbetapentane/Guaifenesin Sustained-Release Capsules are used for:

Relieving unproductive cough and reducing mucus in the chest due to colds, flu, or hay fever. It may also be used for other conditions as determined by your doctor.

Carbetapentane/Guaifenesin Sustained-Release Capsules are a cough suppressant and expectorant combination. The cough suppressant works in the brain to help decrease the cough reflex. The expectorant works by thinning mucus (phlegm) in the lungs, making it less sticky and easier to cough up. This makes coughs more productive.

Do NOT use Carbetapentane/Guaifenesin Sustained-Release Capsules if: you are allergic to any ingredient in Carbetapentane/Guaifenesin Sustained-Release Capsules

Contact your doctor or health care provider right away if any of these apply to you.

Before using Carbetapentane/Guaifenesin Sustained-Release Capsules:

Some medical conditions may interact with Carbetapentane/Guaifenesin Sustained-Release Capsules. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement if you have allergies to medicines, foods, or other substances if you have chronic cough due to smoking, asthma, chronic bronchitis, or emphysema, or if your cough produces large amounts of mucus if you have a history of heart problems, high blood pressure, prostate problems, an overactive thyroid, diabetes, or glaucoma

Some MEDICINES MAY INTERACT with Carbetapentane/Guaifenesin Sustained-Release Capsules. Tell your health care provider if you are taking any other medicines. However, no specific interactions with Carbetapentane/Guaifenesin Sustained-Release Capsules are known at this time.

This may not be a complete list of all interactions that may occur. Ask your health care provider if Carbetapentane/Guaifenesin Sustained-Release Capsules may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Carbetapentane/Guaifenesin Sustained-Release Capsules:

Use Carbetapentane/Guaifenesin Sustained-Release Capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Carbetapentane/Guaifenesin Sustained-Release Capsules may be taken with or without food. Drinking extra fluids while you are taking Carbetapentane/Guaifenesin Sustained-Release Capsules are recommended. Check with your doctor for instructions. Swallow Carbetapentane/Guaifenesin Sustained-Release Capsules whole. Do not break, crush, or chew before swallowing. If you miss a dose of Carbetapentane/Guaifenesin Sustained-Release Capsules and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Carbetapentane/Guaifenesin Sustained-Release Capsules.

Important safety information: Carbetapentane/Guaifenesin Sustained-Release Capsules may cause drowsiness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Carbetapentane/Guaifenesin Sustained-Release Capsules. Using Carbetapentane/Guaifenesin Sustained-Release Capsules alone, with certain other medicines, or with alcohol may lessen your ability to drive or perform other potentially dangerous tasks. Avoid drinking alcohol or taking other medications that cause drowsiness (eg, sedatives, tranquilizers) while taking Carbetapentane/Guaifenesin Sustained-Release Capsules. Carbetapentane/Guaifenesin Sustained-Release Capsules will add to the effects of alcohol and other depressants. Ask your pharmacist if you have questions about which medicines are depressants. If cough persists for more than 1 week or is accompanied by a fever, contact your health care provider. A persistent cough could be a sign of a serious condition. Carbetapentane/Guaifenesin Sustained-Release Capsules are not recommended for use in CHILDREN younger than 6 years of age. Safety and effectiveness in this age group have not been confirmed. PREGNANCY and BREAST-FEEDING: If you become pregnant, discuss with your doctor the benefits and risks of using Carbetapentane/Guaifenesin Sustained-Release Capsules during pregnancy. It is unknown if Carbetapentane/Guaifenesin Sustained-Release Capsules are excreted in breast milk. If you are or will be breast-feeding while you are using Carbetapentane/Guaifenesin Sustained-Release Capsules, check with your doctor or pharmacist to discuss the risks to your baby. Possible side effects of Carbetapentane/Guaifenesin Sustained-Release Capsules:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Drowsiness; dry mouth, nose, or throat; upset stomach.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Carbetapentane/Guaifenesin side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include restlessness; seizures; severe agitation.

Proper storage of Carbetapentane/Guaifenesin Sustained-Release Capsules:

Store Carbetapentane/Guaifenesin Sustained-Release Capsules at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Carbetapentane/Guaifenesin Sustained-Release Capsules out of the reach of children and away from pets.

General information: If you have any questions about Carbetapentane/Guaifenesin Sustained-Release Capsules, please talk with your doctor, pharmacist, or other health care provider. Carbetapentane/Guaifenesin Sustained-Release Capsules are to be used only by the patient for whom it is prescribed. Do not share it with other people. If your symptoms do not improve or if they become worse, check with your doctor. Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Carbetapentane/Guaifenesin Sustained-Release Capsules. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012 Database Edition 12.1.1.002 Copyright © 2012 Wolters Kluwer Health, Inc. More Carbetapentane/Guaifenesin resources Carbetapentane/Guaifenesin Side Effects (in more detail) Carbetapentane/Guaifenesin Use in Pregnancy & Breastfeeding Carbetapentane/Guaifenesin Drug Interactions Carbetapentane/Guaifenesin Support Group 0 Reviews for Carbetapentane/Guaifenesin - Add your own review/rating Compare Carbetapentane/Guaifenesin with other medications Cough
read more / Download


Bartonellosis Medications


Definition of Bartonellosis: Cat scratch disease is an infectious illness caused by the bacteria More...

Drugs associated with Bartonellosis

The following drugs and medications are in some way related to, or used in the treatment of Bartonellosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Learn more about Bartonellosis

Medical Encyclopedia:

Cat scratch disease
Drug List: Azithromycin-3-Day-Dose-Pack Doryx-Delayed-Release-Capsules Doxy-100 Doxy-200 E-E-S-Granules-Suspension E-E-S-200 E-E-S-400 E-E-S-400-Filmtab Ery-Tab Eryc-Delayed-Release-Particles-Capsules Eryped-Drops Erythrocin Erythromycin-Lactobionate-I-V Erythrocin-Stearate-Filmtab Ilosone Monodox Ocudox-Convenience-Kit Oraxyl Pce Rifadin Rifadin-Iv Rimactane Vibra-Tabs Vibramycin Zithromax Zmax-Extended-Release-Oral-Suspension
read more / Download


ADHD (Attention Deficit Hyperactivity Disorder) Medications


Definition of ADHD: An inability to control behaviour due to difficulty in processing neural stimuli. More...

Drugs associated with ADHD

The following drugs and medications are in some way related to, or used in the treatment of ADHD. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under ADHD Oppositional Defiant Disorder (1 drug) Learn more about ADHD (Attention Deficit Hyperactivity Disorder)

Medical Encyclopedia:

Attention deficit hyperactivity disorder (ADHD)

Drugs.com Health Center:

Mental Health Disorders
Drug List: 5-Htp Adderall Adderall-Xr-Extended-Release-Capsules Aminomine Animi-3 Animi-3-With-Vitamin-D Concerta Cylert Daytrana Desoxyn Desoxyn-Gradumet Dexedrine Dextrostat Divista Eldepryl Epa-Fish-Oil Fish_Oil Fish-Oil-Ultra Focalin Focalin-Xr-Extended-Release-Capsules Icar-Prenatal-Essential-Omega-3 Intuniv Kapvay Liquadd-Solution Lovaza Marine-Lipid-Concentrate Maxepa Maxitears-Dry-Eye-Formula Maxivision-Omega-3-Formula Metadate-Cd-Controlled-Release-Capsules Metadate-Er Methylin Methylin-Er-Controlled-Release-Tablets Mi-Omega Mi-Omega-Nf Norpramin Omacor Omega-500 Pristiq Procentra-Solution Proepa Ritalin Ritalin-La-Extended-Release-Capsules Ritalin-Sr-Controlled-Release-Tablets Sea-Omega Sea-Omega-30 Sea-Omega-70 Strattera Theratears-Nutrition Theromega Tofranil Tofranil-Pm Vyvanse Zelapar
read more / Download


Related Search:

Search


 

Best ED Pills

 

Erectile Dysfunction

 

RX Pharmacy Drugs List - Buy Pills Online

RSS | Site Map | Map | PageMap

Copyright © Online Pharmacy Drug Store. All rights reserved.